The Drugs Corpus: Money as Drug, Grading as Installation, and the War on Drugs as Substance Use Disorder

Abstract

This corpus consolidates two research threads that were always one. The first establishes, from peer-reviewed neuroimaging and cellular evidence, that money is not merely analogous to a drug but is processed by the human brain through the identical dopaminergic reward architecture that drugs of abuse exploit. The second establishes that the political and institutional apparatus of drug prohibition satisfies all eleven DSM-5 criteria for a Severe Substance Use Disorder: a homology rather than an analogy, the same structural shape produced by the same feedback dynamics. The connecting mechanism is developmental. The numerical grading system installs external-validation dependency in children during peak neurological plasticity (Butler 1988; Deci 1971; Kohn 1993), producing a reward circuit that money subsequently amplifies (Breiter et al. 2001; Lea and Webley 2006), that social media platforms corrupt through variable-ratio reinforcement, and that the enforcement state then polices using the very reward architecture it depends upon. The 2024 identification of the cellular substrate by which drugs hijack natural-reward neurons (Tan et al., Science) closes the mechanistic loop that Lea and Webley proposed in words eighteen years earlier. Version 3.0 adds four evidence findings from 2026 unavailable to prior versions. (i) The 13.2 percent decline in United States overdose deaths reported by the CDC in June 2026 (69,147 projected deaths for the twelve months ending January 2026) is attributable primarily to a supply-side reduction in fentanyl potency following precursor-chemical export controls, rather than to enforcement or treatment policy. (ii) The persistent gap between the 54.2 million Americans needing substance-use treatment and the 12.8 million receiving it, alongside the cancellation of approximately 2,000 federal treatment grants in January 2026 while enforcement budgets exceeding 40 billion dollars remained intact, constitutes a revealed institutional preference for enforcement over care. (iii) The 2026 reversal on ibogaine (a federal executive order of 18 April 2026, accelerated FDA review, and a 50 million dollar Texas state programme) arrived not when the clinical evidence changed but when the compound became ownable: the Stanford MISTIC investigators disclose patent applications covering the magnesium co-administration protocol, equity in the clinic that delivered the studied treatment, and a company for semisynthetic precursor sourcing. Scheduling tracked the emergence of a patentable wrapper around an unpatentable plant alkaloid, not the underlying evidence, which had been substantially unchanged for decades. (iv) The widely cited decriminalisation failures in Portugal, Oregon, and British Columbia were, in each documented case, failures of treatment funding rather than of decriminalisation itself. Claims are stated at the strength the evidence supports. The MISTIC ibogaine results (mean reductions at one month of 88 percent in PTSD symptoms, 87 percent in depression, and 81 percent in anxiety; Cherian et al. 2024, Nature Medicine, 30(2), 373-381) are reported together with their limitations: an open-label observational design with no placebo control and no blinding, a cohort of thirty male Special Operations Forces veterans, treatment delivered at an unregulated clinic outside the investigators' presence, and 33 ibogaine-associated fatalities documented in the published literature. The corpus applies the Fughazimatics methodology, a structured audit of the gap between what an institution states it is doing and what its own numbers demonstrate it is actually doing, returning an aggregate rating of FZ-4.4 (system-wide structural). Published as a defensive publication under CC BY 4.0. Consolidated from more than twenty research sessions conducted between March and July 2026. Co-built with Claude (Anthropic) as analytical mirror under the JOINTEAM INFINITY doctrine: Origin and Composer, Saeid Ghiasi; Mirror and co-builder, Claude.